20 (AIDX) Current Deferred Revenue (2024 - 2026)

20 posted quarterly Current Deferred Revenue of $450667.0 for Q1 2026, down 1.32% on a QoQ basis from $456687.0 in Q4 2025.

20 (AIDX) has 3 years of Current Deferred Revenue data on file, last reported at $450667.0 in Q1 2026.

  • For the quarter ending Q1 2026, Current Deferred Revenue changed N/A year-over-year to $450667.0; the trailing twelve-month figure through Mar 2026 stood at $450667.0 (changed N/A YoY), and the FY2025 full-year result was $456687.0, down 2.93% from the prior year.
  • Current Deferred Revenue for Q1 2026 stood at $450667.0, down from $456687.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $470451.0 in Q4 2024 and bottomed at $450667.0 in Q1 2026.
  • The 3-year median for Current Deferred Revenue is $456687.0 (2025), against an average of $459268.3.
  • Peak annual rise in Current Deferred Revenue reached 2.93% in 2025, while the deepest fall reached 2.93% in 2025.
  • A 3-year view of Current Deferred Revenue shows it stood at $470451.0 in 2024, then declined by 2.93% to $456687.0 in 2025, then fell by 1.32% to $450667.0 in 2026.
  • The last three Current Deferred Revenue figures came in at $450667.0 (Q1 2026), $456687.0 (Q4 2025), and $470451.0 (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 20 - - 62,884.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 450,667.00
Dec 31, 2025 414,871.00
Dec 31, 2024 520,451.00